Guangjian Yang

910 total citations
56 papers, 602 citations indexed

About

Guangjian Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Guangjian Yang has authored 56 papers receiving a total of 602 indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Guangjian Yang's work include Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (9 papers). Guangjian Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (37 papers), Lung Cancer Research Studies (20 papers) and Colorectal Cancer Treatments and Studies (9 papers). Guangjian Yang collaborates with scholars based in China, United States and United Kingdom. Guangjian Yang's co-authors include Yan Wang, Haiyan Xu, Lu Yang, Yaning Yang, Fei Xu, Junling Li, Xuezhi Hao, Jianming Ying, Weihua Li and Puyuan Xing and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Guangjian Yang

53 papers receiving 592 citations

Peers

Countries citing papers authored by Guangjian Yang

Since Specialization

Citations

This map shows the geographic impact of Guangjian Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guangjian Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guangjian Yang more than expected).

Fields of papers citing papers by Guangjian Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guangjian Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guangjian Yang. The network helps show where Guangjian Yang may publish in the future.

Co-authorship network of co-authors of Guangjian Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Guangjian Yang. A scholar is included among the top collaborators of Guangjian Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guangjian Yang. Guangjian Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus 2025 ·World Journal of Diabetes ·Xuedong An, Xueqin Li, (unknown), (unknown), Yuehong Zhang, Guangjian Yang	0
2	Dynamic characterization of circulating tumor DNA in HER2-altered advanced non-small cell lung cancer treated with pyrotinib and apatinib: Exploratory biomarker analysis from PATHER2 study 2024 ·Lung Cancer ·(unknown), Guangjian Yang, Yaning Yang, Yuanqiang Zhang, Yan Wang, Haiyan Xu	1
3	Phase I/II clinical trial of efficacy and safety of EGCG oxygen nebulization inhalation in the treatment of COVID-19 pneumonia patients with cancer 2024 ·BMC Cancer ·Xiaoyan Yin, Wanqi Zhu, (unknown), Guangjian Yang, Xianguang Zhao, Kaikai Zhao, (unknown), Xiaolin Li, (unknown), Xin Wang, Yuanyuan Yan, Ligang Xing, Jinming Yu, Xiangjiao Meng, Hanxi Zhao	9
4	Abstract 3263: VEGFA mediates traditional EGFR-TKI resistance in non-small cell lung cancer with EGFR exon 20 insertions 2024 ·Cancer Research ·Yaning Yang, Chengming Liu, Guangjian Yang, Haiyan Xu, (unknown), Y Wang	1
5	Pyrotinib plus antiangiogenic agents for HER2‐altered advanced non‐small cell lung cancer: A retrospective real‐world study 2023 ·Thoracic Cancer ·Yaning Yang, Guangjian Yang, Weihua Li, Xuezhi Hao, Yuanqiang Zhang, Xin Ai, (unknown), Haiyan Xu, Yan Wang	5
6	The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study 2023 ·Cancer Medicine ·(unknown), Lu Yang, Yaning Yang, Guangjian Yang, Haiyan Xu, Xueliang Niu, Yan Wang	3
7	Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China 2022 ·Frontiers in Pharmacology ·(unknown), Guangjian Yang, Yi Cai, Junling Li, Haiyan Xu, Tao Zhang, Liqiang Zhou, Yuying Wang, Jinliang Wang, Xingsheng Hu, Xiang Yan, (unknown), (unknown)	8
8	Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2) 2022 ·BMC Medicine ·Guangjian Yang, Haiyan Xu, Yaning Yang, Yuanqiang Zhang, Fei Xu, Xuezhi Hao, Junling Li, Puyuan Xing, Xingsheng Hu, Yutao Liu, Lin Wang, Lin Lin, Zhijie Wang, Jianchun Duan, Jie Wang, Yan Wang	25
9	A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients 2022 ·Frontiers in Oncology ·Fei Xu, Haiyan Xu, Zhiyi Wan, Guangjian Yang, Yang Lü, Xueying Wu, Jin Sook Song, Yan Wang	3
10	EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors 2022 ·Frontiers in Pharmacology ·Guangjian Yang, Yaning Yang, Jiaqi Hu, Haiyan Xu, Yuanqiang Zhang, Yan Wang	5
11	Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors 2022 ·Frontiers in Pharmacology ·Guangjian Yang, Haiyan Xu, Jiaqi Hu, (unknown), (unknown), Yaning Yang, (unknown), Xuezhi Hao, Yuanqiang Zhang, Fei Xu, Xin Ai, Junling Li, Yan Wang	4
12	Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients 2021 ·Cancer Medicine ·Yaning Yang, Haiyan Xu, Li Ma, Lu Yang, Guangjian Yang, (unknown), (unknown), Xin Ai, Shucai Zhang, Yan Wang	11
13	Case Report: Dacomitinib May Not Benefit Patients Who Develop Rare Compound Mutations After Later-Line Osimertinib Treatment 2021 ·Frontiers in Oncology ·(unknown), Guangjian Yang, Yan Wang	12
14	EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study 2020 ·Lung Cancer ·Guangjian Yang, Jun Li, Haiyan Xu, Yaning Yang, Lu Yang, Fei Xu, Bing Xia, Viola W. Zhu, Misako Nagasaka, Yan Yang, (unknown), (unknown), Jianming Ying, Sai‐Hong Ignatius Ou, Yan Wang	75
15	Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study 2020 ·Lung Cancer ·Guangjian Yang, Haiyan Xu, Lu Yang, Fei Xu, Yuanqiang Zhang, Yaning Yang, Yan Wang	8
16	<p>Tumor Differentiation and <em>EGFR</em> Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery</p> 2020 ·Cancer Management and Research ·Lu Yang, Chong Pang, Fei Xu, Guangjian Yang, Haiyan Xu, Changli Wang, Yan Wang	3
17	Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma 2020 ·Translational Oncology ·Lu Yang, Jing Zhang, (unknown), Guangjian Yang, Haiyan Xu, Junling Li, Lei Guo, (unknown), (unknown), Beibei Mao, Ying Yang, Lijia Wu, (unknown), Henghui Zhang, Jianming Ying, Yan Wang	3
18	SuhB Regulates the Motile-Sessile Switch in Pseudomonas aeruginosa through the Gac/Rsm Pathway and c-di-GMP Signaling 2017 ·Frontiers in Microbiology ·Kewei Li, Guangjian Yang, (unknown), Pingping Li, (unknown), Peizhen Li, Teng Xu, Weihui Wu, Shouguang Jin, Qiyu Bao	30
19	Structure-Function Analysis of the Transmembrane Protein AmpG from Pseudomonas aeruginosa 2016 ·PLoS ONE ·Peizhen Li, Jun Ying, Guangjian Yang, (unknown), Jian Wang, Junwan Lu, Junrong Wang, Teng Xu, Huiguang Yi, Kewei Li, Shouguang Jin, Qiyu Bao, Kaibo Zhang	12
20	Effects of phycoerythrin from Gracilaria lemaneiformis in proliferation and apoptosis of SW480 cells 2016 ·Oncology Reports ·Peizhen Li, Jun Ying, (unknown), Wen Zhu, Guangjian Yang, Teng Xu, Huiguang Yi, (unknown), (unknown), Xiaofeng Zeng, Chunxia Yan, Qiyu Bao, Shengbin Li	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact